HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period.

AuthorsM Megna, G Fabbrocini, E Camela, E Cinelli
JournalJournal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 34 Issue 11 Pg. e705-e707 (Nov 2020) ISSN: 1468-3083 [Electronic] England
PMID32277507 (Publication Type: Letter)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Thalidomide
  • apremilast
Topics
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
  • Humans
  • Psoriasis (drug therapy)
  • Severity of Illness Index
  • Thalidomide (analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: